Usefulness of Plasma SARS-CoV-2 RNA Quantification by Droplet-based Digital PCR to Monitor Treatment Against COVID-19 in a B-cell Lymphoma Patient

Szwebel, Tali Anne; Veyer, David; Robillard, Nicolas; Eshagh, Déborah; Canouï, Etienne; Bruneau, Thomas; Contejean, Adrien; Azoulay, Célia; Serrano, Thomas; Hueso, Thomas; Izquierdo, Laure; Rozenberg, Flore; Terrier, B.; Vignon, Marguerite; Laurent‐Puig, Pierre; Taly, Valérie; Bélec, Laurent; Kernéis, Solen; Lacombe, Karine; Péré, Hélène

doi:10.1007/s12015-020-10107-5

Cited by 18 publications

(16 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An overall of 3651 samples, from 2825 patients and 145 controls, were extracted from the 39 included studies. The studies were conducted worldwide; 16 in Asia [ 12 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 ], 14 in Europe [ 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 ], and 9 in North America [ 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 ]. A minority of studies (8) included control samples [ 21 , 28 , 29 , 33 , 38 , 47 , 54 , 56 ].…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Diagnostic, Prognostic, and Therapeutic Value of Droplet Digital PCR (ddPCR) in COVID-19 Patients: A Systematic Review

Ishak

AlRawashdeh

Esagian

et al. 2021

JCM

View full text Add to dashboard Cite

Accurate detection of SARS-CoV-2, the pathogen causing the global pandemic of COVID-19, is essential for disease surveillance and control. Quantitative reverse transcription PCR (RT-qPCR) is considered the reference standard test for the diagnosis of SARS-CoV-2 by the World Health Organization and Centers for Disease Control and Prevention. However, its limitations are a prompt for a more accurate assay to detect SARS-CoV-2, quantify its levels, and assess the prognosis. This article aimed to systematically review the literature and assess the diagnostic performance of droplet digital PCR (ddPCR), also to evaluate its potential role in prognosis and management of COVID-19 patients. PubMed and Scopus databases were searched to identify relevant articles published until 13 July 2021. An additional PubMed search was performed on 21 October 2021. Data from the 39 eligible studies were extracted and an overall 3651 samples from 2825 patients and 145 controls were used for our qualitative analysis. Most studies reported ddPCR was more accurate than RT-qPCR in detecting and quantifying SARS-CoV-2 levels, especially in patients with low viral loads. ddPCR was also found highly effective in quantifying SARS-CoV-2 RNAemia levels in hospitalized patients, monitoring their disease course, and predicting their response to therapy. These findings suggest ddPCR could serve as a complement or alternative SARS-CoV-2 tool with emerging diagnostic, prognostic, and therapeutic value, especially in hospital settings. Additional research is still needed to standardize its laboratory protocols, also to accurately assess its role in monitoring COVID-19 therapy response and in identifying SARS-CoV-2 emerging variants.

show abstract

Section: Resultsmentioning

confidence: 99%

“…Other commonly used sources were the blood, plasma, saliva, oropharyngeal, sputum, and respiratory excretions. Some studies also reported the use of rectal, urine, and bronchoalveolar lavage (BAL) samples [ 30 , 44 , 45 ]. One study reported using colostrum samples [ 55 ].…”

Section: Resultsmentioning

confidence: 99%

Diagnostic, Prognostic, and Therapeutic Value of Droplet Digital PCR (ddPCR) in COVID-19 Patients: A Systematic Review

Ishak

AlRawashdeh

Esagian

et al. 2021

JCM

View full text Add to dashboard Cite

show abstract

“…Bertrains et al demonstrated that protracted Covid-19 in patients with B-cell lymphoma is associated with a lack of significant neutralizing antibody titers and impaired clearance of SARS-CoV-2 and that treatment with hyperimmune plasma resulted in an increase in neutralizing antibody titers and a clinical response [13]. In addition, Szwebel et al analyzed the SARS-CoV-2 viral load (i.e., RNAaemia) in a hematologic patient affected by Covid-19 and treated with convalescent plasma and they observed a persistently high level of RNAaemia during the whole course of the disease and a rapid negativization after the administration of hyperimmune plasma, correlated with complete clinical recovery [14].…”

Section: Discussionmentioning

confidence: 99%

Hyperimmune plasma infusion in an immunocompromised Covid-19 patient previously treated for follicular lymphoma

Levi

Rocchetti

Magri

et al. 2021

Monaldi Arch Chest Dis

View full text Add to dashboard Cite

Covid-19 in immunocompromised patients shows a prolonged course and may lead to a poor prognosis. Although data on hyperimmune plasma for treatment of Covid-19 suggest an improved outcome in immunocompetent patients, limited data are currently available in immunocompromised patients. We present the case of a 62-year-old Caucasian woman, who was previously treated with obinutuzumab and bendamustine for follicular lymphoma and showed a prolonged positive test for Covid-19. Since no improvement was observed with standard of care (including remdesivir), the possibility of hyperimmune plasma infusion was discussed. A first dose of hyperimmune plasma was administered, with subsequent onset of fever, increasing inflammatory indexes and worsening radiological findings. Three days later a second dose of plasma was administered. Within twelve hours cough and fever disappeared, and oxygen at rest was discontinued. The patient was discharged 5 days later, and nasopharyngeal swabs resulted negative 16 days after discharge.

show abstract

“…This lack of protective correlation may be one of the reasons behind the disappointing therapeutic efficacy of convalescent plasma therapy. Indeed, after a promising first observational study [ 317 ] and good results in patients with acquired immunodeficiency [ 318 , 319 ], several double blind, placebo controlled clinical trials failed to show any efficacy for this approach [ 320 , 321 ]. In this context, the recent success of the mRNA- and viral-vector based vaccines against SARS-CoV-2 are of particular interest and raise several hypotheses: (i) antibodies against SARS-CoV-2 are more efficient as a prophylactic treatment than a therapeutic one, (ii) the antibodies generated by the vaccines are different from the naturally occurring ones and/or (iii) other components of the immune system are triggered by the vaccines.…”

Section: Immune Reaction Vaccination and Thrombosismentioning

confidence: 99%

COVID-19 is a systemic vascular hemopathy: insight for mechanistic and clinical aspects

et al. 2021

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is presenting as a systemic disease associated with vascular inflammation and endothelial injury. Severe forms of SARS-CoV-2 infection induce acute respiratory distress syndrome (ARDS) and there is still an ongoing debate on whether COVID-19 ARDS and its perfusion defect differs from ARDS induced by other causes. Beside pro-inflammatory cytokines (such as interleukin-1 β [IL-1β] or IL-6), several main pathological phenomena have been seen because of endothelial cell (EC) dysfunction: hypercoagulation reflected by fibrin degradation products called D-dimers, micro- and macrothrombosis and pathological angiogenesis. Direct endothelial infection by SARS-CoV-2 is not likely to occur and ACE-2 expression by EC is a matter of debate. Indeed, endothelial damage reported in severely ill patients with COVID-19 could be more likely secondary to infection of neighboring cells and/or a consequence of inflammation. Endotheliopathy could give rise to hypercoagulation by alteration in the levels of different factors such as von Willebrand factor. Other than thrombotic events, pathological angiogenesis is among the recent findings. Overexpression of different proangiogenic factors such as vascular endothelial growth factor (VEGF), basic fibroblast growth factor (FGF-2) or placental growth factors (PlGF) have been found in plasma or lung biopsies of COVID-19 patients. Finally, SARS-CoV-2 infection induces an emergency myelopoiesis associated to deregulated immunity and mobilization of endothelial progenitor cells, leading to features of acquired hematological malignancies or cardiovascular disease, which are discussed in this review. Altogether, this review will try to elucidate the pathophysiology of thrombotic complications, pathological angiogenesis and EC dysfunction, allowing better insight in new targets and antithrombotic protocols to better address vascular system dysfunction. Since treating SARS-CoV-2 infection and its potential long-term effects involves targeting the vascular compartment and/or mobilization of immature immune cells, we propose to define COVID-19 and its complications as a systemic vascular acquired hemopathy.

show abstract

Usefulness of Plasma SARS-CoV-2 RNA Quantification by Droplet-based Digital PCR to Monitor Treatment Against COVID-19 in a B-cell Lymphoma Patient

Cited by 18 publications

References 6 publications

Diagnostic, Prognostic, and Therapeutic Value of Droplet Digital PCR (ddPCR) in COVID-19 Patients: A Systematic Review

Diagnostic, Prognostic, and Therapeutic Value of Droplet Digital PCR (ddPCR) in COVID-19 Patients: A Systematic Review

Hyperimmune plasma infusion in an immunocompromised Covid-19 patient previously treated for follicular lymphoma

COVID-19 is a systemic vascular hemopathy: insight for mechanistic and clinical aspects

Contact Info

Product

Resources

About